GSK Receives European Approval for Three Additional Indications of Nucala November 19, 2021 Auto Bot News 0 GSK has been granted approval by the EC for its monoclonal antibody therapy, Nucala (mepolizumab), as a treatment for three additional eosinophil-driven diseases.